Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347559 | 0.80 | ALOX15 (0.48) | MEN1MAPTKMT2AL3MBTL1KDM4E | |
| SCHEMBL2669086 | 0.77 | ALOX15 (0.41) | MEN1MAPTKMT2AL3MBTL1KDM4E | |
| SCHEMBL2669124 | 0.75 | ALOX15 (0.43) | MEN1MAPTKMT2AKDM4EALOX15 | |
| SCHEMBL3622722 | 0.73 | CHEK1 (0.39) | CHEK1LTA4H | |
| SCHEMBL5875892 | 0.72 | HSD17B10 (0.39) | TSHRNPC1RAB9A | |
| SCHEMBL30620404 | 0.72 | SMN1; SMN2 (0.53) | MEN1MAPTKMT2AL3MBTL1KDM4E | |
| SCHEMBL13639771 | 0.70 | CCNE2 (0.57) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL16762644 | 0.70 | GRIN2B (0.40) | L3MBTL1KDM4ELTA4HHRH3 | |
| SCHEMBL1000315 | 0.70 | CCNE2 (0.41) | MAPTSMN1; SMN2 | |
| SCHEMBL999780 | 0.70 | CCNE2 (0.41) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379517-B1 | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20100160395-A1 | CYCLOPROPYL COMPOUNDS | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160395-A1 | CYCLOPROPYL COMPOUNDS | IAPP, GPR119, SLC5A2 | MEN1 2668/4885MAPT 1990/4885KMT2A 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.